POPULATION-LEVEL IMPACT OF POLATUZUMAB AND GLOFITAMAB IN ALGERIA: A 15-YEAR PROJECTION
Author(s)
Amira DENBRI, PharmD1, Nawel Djadi, PharmD1, Dallel Yamina Laloui, PharmD1, Khalifa Islam BENGANA, PharmD2, Abdelhakim Boudis, Professor1.
1University of Health Sciences of Algiers, Algiers, Algeria, 2Roche Algérie SPA, Algiers, Algeria.
1University of Health Sciences of Algiers, Algiers, Algeria, 2Roche Algérie SPA, Algiers, Algeria.
OBJECTIVES: Diffuse large B-Cell lymphoma (DLBCL) is the most aggressive form of non-Hodkin lymphoma (NHL). Its management in Algeria faces therapeutic impasses and substantial societal burdens. This study evaluates the clinical, economic, and societal impact, including a comparison between standard and societal incremental cost-effectiveness ratios (ICERs), of integrating polatuzumab vedotin (first-line) and glofitamab (second-line) into the Algerian health care system over a 15-year time horizon.
METHODS: A treatment impact model (TIM) was utilized to project the overall outcomes: clinical endpoints (remission, relapse), quality-adjusted life-years (QALYs), indirect costs, and productivity losses by comparing the reference scenario (R-CHOP and salvage regimens) with a prospective scenario (innovative therapies). Both standard and societal ICERs were calculated to determine the value of the intervention by incorporating productivity gains and preserved human capital. Data were collected from 8 national hospital centers.
RESULTS: Integration of these therapies improved clinical outcomes, with an 8% increase in remissions (426 additional patients) and a 22.3% reduction in relapses over 15 years. This therapeutic shift resulted in a cumulative gain of 366 QALYs. Regarding societal impact, the study projected a 59.5% reduction in days of work incapacity, preserving 374,040 working days and generating a productivity gain of 493 million Algerian dinars (DZD) (3.4 million €). Integrating these indirect societal benefits reduced the cost-utility ratio by 9% compared to the standard ICER (13.9 million DZD/QALY vs 15.3million DZD/QALY), highlighting the strategic value of restoring patient productivity.
CONCLUSIONS: The adoption of polatuzumab and glofitamab represents a major clinical and societal advancement for DLBCL management in Algeria.The comparative ICER analysis confirms that these therapies act as a strategic investment, shifting policy focus from simple cost containment to holistic, value-based health care that optimizes national productivity and improves patient quality of life.
METHODS: A treatment impact model (TIM) was utilized to project the overall outcomes: clinical endpoints (remission, relapse), quality-adjusted life-years (QALYs), indirect costs, and productivity losses by comparing the reference scenario (R-CHOP and salvage regimens) with a prospective scenario (innovative therapies). Both standard and societal ICERs were calculated to determine the value of the intervention by incorporating productivity gains and preserved human capital. Data were collected from 8 national hospital centers.
RESULTS: Integration of these therapies improved clinical outcomes, with an 8% increase in remissions (426 additional patients) and a 22.3% reduction in relapses over 15 years. This therapeutic shift resulted in a cumulative gain of 366 QALYs. Regarding societal impact, the study projected a 59.5% reduction in days of work incapacity, preserving 374,040 working days and generating a productivity gain of 493 million Algerian dinars (DZD) (3.4 million €). Integrating these indirect societal benefits reduced the cost-utility ratio by 9% compared to the standard ICER (13.9 million DZD/QALY vs 15.3million DZD/QALY), highlighting the strategic value of restoring patient productivity.
CONCLUSIONS: The adoption of polatuzumab and glofitamab represents a major clinical and societal advancement for DLBCL management in Algeria.The comparative ICER analysis confirms that these therapies act as a strategic investment, shifting policy focus from simple cost containment to holistic, value-based health care that optimizes national productivity and improves patient quality of life.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR22
Topic
Economic Evaluation, Patient-Centered Research
Topic Subcategory
Patient Engagement
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology